ALEC
USDAlector Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$1.400
最高
$1.435
最低
$1.290
交易量
1.77M
公司基本面
市值
133.6M
行業
生物科技
國家
United States
交易統計
平均交易量
2.62M
交易所
NMS
貨幣
USD
52週範圍
相關新聞
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.
Cantor Fitzgerald Downgrades Alector to Neutral
Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.
William Blair Downgrades Alector to Market Perform
William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.
BTIG Downgrades Alector to Neutral
BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
